Related Experiment Videos
[Neoadjuvant chemoradiotherapy in gallbladder cancer]
Xabier de Aretxabala1, Héctor Losada, Javier Mora
1Servicio de Cirugía, Hospital Regional de Temuco. aretxaba@ufro.cl
Revista Medica De Chile
|September 24, 2004
Summary
Neoadjuvant chemoradiation did not improve prognosis for gallbladder cancer patients and may be detrimental. This study found worse survival rates in treated patients compared to those who did not receive chemoradiation.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Context:
- Gallbladder cancer typically presents with a poor prognosis.
- Local recurrence is the primary pattern of treatment failure.
Purpose:
- To assess the efficacy of neoadjuvant chemoradiation in improving gallbladder cancer prognosis.
- To compare outcomes of patients receiving neoadjuvant chemoradiation with a historical control group.
Summary:
- A prospective study of 23 gallbladder cancer patients treated with 5-fluorouracil chemotherapy and 4500 cGy radiotherapy.
- Significant hematological toxicities (leucopenia, thrombocytopenia) were observed.
- Chemoradiation delayed surgery in 8 patients, with 7 excluded from resection; 14 underwent resection with noted liver/lymph node involvement.
- Actuarial survival was worse in the chemoradiation group compared to 19 historical controls.
Impact:
- Neoadjuvant chemoradiation demonstrated no benefit and a potentially harmful effect in this gallbladder cancer cohort.
- Findings suggest current neoadjuvant chemoradiation protocols may negatively impact patient outcomes.
- Further research is needed to explore alternative or optimized neoadjuvant strategies for gallbladder cancer.